Postdoctoral Research Fellow In Cancer Immunology

Cleveland Clinic

Cleveland, OH

ID: 7059295
Posted: August 14, 2019
Application Deadline: Open Until Filled

Job Description

Postdoctoral fellow positions are available in Dr. Li Lily Wang’s laboratory, in the department of Translational Hematology Oncology Research (THOR), https://www.lerner.ccf.org/thor/wang/  in the Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH. The Wang laboratory is engaging in cross-disciplinary studies by collaborating with basic and clinical researchers from LRI /CCF and the Case Comprehensive Cancer Center, affiliated with Case Western Reserve University.

Immune-checkpoint blockade (ICB) therapies have revolutionized the field of Cancer Immunotherapy. However, the low response rate in a majority of patients indicates the urgent need to identify and target additional checkpoint regulators. The Wang laboratory is among the first group to demonstrate that the immune-checkpoint protein “V domain Immunoglobulin Suppressor of T cell Activation” (VISTA) is a promising target for cancer immunotherapy (1 – 6). Our studies show that VISTA regulates the effector functions of cytotoxic T cells, myeloid-derived suppressor cells (MDSC), and myeloid inflammatory DCs. Current projects are focusing on elucidating the molecular signaling mechanisms of VISTA and design innovative approaches to target this checkpoint protein for cancer therapy.

We seek talented and committed candidates with a recent Ph.D. in Biochemistry, Cell Biology, Immunology, or other relevant branches of biological sciences to join our team and make significant contributions to the field of Cancer Immunotherapy. Interested candidates should submit CV, a statement of research interests in a cover letter, and three references to Dr. Li Lily Wang, wangl9@ccf.org.

References:

 

1.Wang L, RubinsteinR, Lines LJ, Wasiuk A, AhonenC, GuoYX, LuLF, Gondek D, WangY, Fava RA, Fiser A, Almo S and Noelle RJ. (2011) ­­­VISTA, a novel Ig-superfamily ligand that negatively regulates T cell responses, J Exp Med. 208(3):577-92. PMC3058578

2. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, Noelle RJ, Wang L (2014) VISTA regulates the development of protective anti-tumor immunity. Cancer Research, 74:1933-1944. PMC4116689

3. Wang L, Le Mercier I, Putra J, Chen W, Liu J, Schenk AD, Nowak EC, Suriawinata AA, Li J, Noelle RJ. (2014) Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. PNAS.  (41):14846-51 PMC4205642

4. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller H, Guleria I, Barth RJ, Huang YH, Wang L (2015) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. PNAS. 112(21):6682-7, PMC4450438

5. Xu W, Tạ MH, Malarkannan S, Wang L(2018) Review: The structure, expression, and function of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular & Molecular Immunology. 2018 May 15(5):438-446 PMC6068175

6. Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta H, Miller H, Olson M, Rajasekaran K, Ernstoff M, Wang D, Malarkannan S, Wang L (2019) Immune checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunology Research 

doi: 10.1158/2326-6066.CIR-18-0489. [Epub ahead of print]



Cleveland Clinic is pleased to be an equal employment/affirmative action employer: Women/Minorities/Veterans/Individuals with Disabilities. Smoke/drug free environment.



 

Apply Now

Please mention to the employer that you saw this ad on UniversityJobs.com